Recent Updates
Recently added Catalysts
BIVI Negative Sentiment Score: 25/100

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is conducting an investigation into BioVie Inc. on behalf of long-term stockholders following a class action complaint alleging that the company's board of directors may have breached their fiduciary duties. The complaint points to multiple failures, including insufficient oversight of a Phase 3 clinical trial and misleading statements regarding the company’s business and compliance practices. Additionally, it highlights that the COVID-19 pandemic adversely affected the company’s ability to conduct proper trial oversight, leading to concerns about the reliability of trial data and potential exclusion of patients. Stockholders are encouraged to contact the firm for more information on their rights.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action complaint alleges misleading statements by BioVie.
  • Concerns about oversight of the Phase 3 clinical trial.
  • COVID-19 pandemic negatively impacted trial oversight.
  • High risk of unreliability in clinical trial data due to oversight issues.

Full Press Release Details

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioVie Inc. (NASDAQ: BIVI) on behalf of long-term stockholders following a class action complaint that was filed against BioVie on January 19, 2024 with a Class Period from August 5, 2021 to November 29, 2023. Our investigation concerns whether the board of directors of BioVie have breached their fiduciary duties to the company.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, it is alleged that Defendants misled investors by failing to disclose that (1) BioVie was not conducting proper oversight of its Phase 3 clinical trial; (2) that the COVID-19 pandemic significantly and negatively impacted the Company’s ability to adequately conduct proper oversight of the Phase 3 clinical trial; (3) that due to lack of proper oversight and reliance on contract research organizations, the data from Defendants’ Phase 3 clinical trial faced a greater risk of being unreliable and that the majority of patients would have to be excluded from the clinical trial; (4) that, as a result of the significant exclusions from the trial results, the Phase 3 clinical trial would fail to meet its primary endpoints; and (5) statements about BioVie’s business, operations, prospects, and compliance with current good clinical practices (“cGCP”) were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
If you are a long-term stockholder of BioVie, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is Bragar Eagel & Squire investigating?

They are investigating claims against BioVie Inc. regarding possible breaches by its board.

What was the class action complaint date against BioVie?

The complaint was filed on January 19, 2024.

What allegations were made against BioVie during the Class Period?

Allegations include misleading statements and improper oversight of clinical trials.

How can BioVie stockholders get more information?

Stockholders can contact Brandon Walker or Marion Passmore via email or phone.

What type of law firm is Bragar Eagel & Squire?

It is a nationally recognized firm representing investors in complex litigation.

Last updated: May 1, 2025